Abstract
As the development of the vaccine against respiratory syncytial virus (VRS) has been rapid recently with the innovation of all sorts of gene engineering tools, it is necessary to analyse the efficacy of all kinds of relevant vaccines comprehensively to accelerate the massive usage of them. In order to achieve it, a systematic analysis was needed along with selecting all kinds of articles published from 2018 to 2020 in various databases (Pubmed, EMBASE and Cochrane library) to get the target data. The procedure was carried out by two independent examiners and supervised by another examiner. Five articles were picked, for a total of 12,719 observed people aged less than 3 months to about 26. The results of the RBM meta-analysis were that the estimated vaccine efficacy was 62% (95% CI: 36% to 78%) with high heterogeneity (I2 = 87%). The subgroup analysis showed that multiple factors contributed to the heterogeneity of the research and indicated that it is better to focus on modifying the vaccine on both infants and adults to prevent the spread of RSV. All in all, compared with other commercial vaccines, the efficacy of the RSV vaccine still needs to be improved and more trials on the safety and immunogenicity have to be operated in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
